Ysios Capital Invests Another $135 Million into Adcendo

Ysios Capital is investing in Adcendo once again. The venture capital firm is reinforcing its investment in the Danish biotechnology company with a record capital injection for the sector in Europe so far this year.

Specifically, Ysios Capital has participated in the Series B round with $135 million in Adcendo. This is the second time that the Spanish asset manager has bet on the Nordic company after having led a Series A round in 2021.

This operation is the largest Series B financing round in the European Union so far this year and one of the most significant for the biotechnology sector. Ysios Capital assures that, with this operation, Europe can compete directly with the United States in cutting-edge biotechnology.

With this expansion, Adcendo will be able to advance, expand and accelerate the development of its pipeline of ADCs designed to address cancer types with previously unmet medical needs.

Ysios Capital has three funds specialized in life sciences

This latest round was led by Tcgx and also included the participation of international investors such as TPG Life Science Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (Citadel) and Logos Capital alongside Ysios Capital.

RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap and Gilde Healthcare, which already had stakes in Adcendo, also participated in the new transaction.

Ysios Capital is a San Sebastian and Barcelona-based asset manager specialising in investments in life sciences companies developing disruptive therapeutic products. Founded in 2008, the company manages more than €400 million through three funds specialising in life sciences and is led by an international team with experience in managing biotechnology companies.

Adcendo is a spin-out company from the University of Copenhagen and Rigshospitalet. It was previously part of the BioInnovation Institute’s Creation House programme, which develops novel immunoconjugated drugs (ADCs) for the treatment of various types of cancer.

The company was founded in 2017 by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from the Finsen Laboratory at Rigshospitalet and the University of Copenhagen, and Henrik Stage, a biotech entrepreneur active in several biotech companies and previously CEO of Santaris Pharma, which was acquired by Roche in 2014.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.